Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 11/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10070055 | 0.88 | AR (0.46) | AR | |
| SCHEMBL10069183 | 0.81 | AR (0.43) | ARPGR | |
| SCHEMBL13179998 | 0.78 | AR (0.41) | ARPGR | |
| SCHEMBL10069420 | 0.75 | AR (0.40) | ARPGR | |
| SCHEMBL10069399 | 0.75 | AR (0.40) | ARPGR | |
| SCHEMBL10069396 | 0.75 | AR (0.40) | ARPGR | |
| SCHEMBL10070050 | 0.75 | AR (0.60) | ARPGR | |
| SCHEMBL10069184 | 0.74 | AR (0.39) | ARPGR | |
| SCHEMBL10069506 | 0.74 | AR (0.62) | ARPGR | |
| SCHEMBL10069182 | 0.73 | AR (0.36) | ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168627-B2 | Helix 12 directed non-steroidal antiandrogens | ENDORECHERCHE, INC. (CA) | 2012-05-01 | — | — | US | disclosed |
| US-20100227855-A1 | HELIX 12 DIRECTED NON-STEROIDAL ANTIANDROGENS | ENDORECHERCHE, INC. (CA) | 2010-09-09 | — | — | US | disclosed |
| US-7709516-B2 | Helix 12 directed non-steroidal antiandrogens | ENDORECHERCHE, INC. (CA) | 2010-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227855-A1 | HELIX 12 DIRECTED NON-STEROIDAL ANTIANDROGENS | AR, SHBG, CYP17A1 | AR 1/4885MEN1 1625/4885LMNA 3371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.